KIMBERLY MCCALPINE: Open Payments
NPI 1598156176 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,162 in 59 payments from 14 companies in 2025. Trend: 2023 $733 · 2024 $1,408 · 2025 $1,162
Food & beverage: $1,162
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 19 | $264 |
| Madrigal Pharmaceuticals | 12 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $145 |
| Intercept Pharmaceuticals, Inc. | 1 | $125 |
| Gilead Sciences, Inc. | 5 | $119 |
| ABBVIE INC. | 6 | $114 |
| Baxter Healthcare | 1 | $43 |
| Mirum Pharmaceuticals, Inc. | 2 | $37 |
| Merck Sharp & Dohme LLC | 1 | $35 |
| Caris MPI, Inc. | 2 | $34 |
Products named: XIFAXAN, REZDIFFRA, LIVTENCITY, OCALIVA, TEFLARO, PERCLOT, Livmarli, KEYTRUDA.
Industry payments across TX — which companies pay providers there.
